A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects
Abstract This study aimed to evaluate the pharmacokinetic (PK) similarity of the proposed biosimilar HS628 compared with the reference tocilizumab (Actemra®) and also to demonstrate similar safety and immunogenicity profiles in healthy Chinese male subjects. Eighty eligible subjects were randomized...
Saved in:
Main Authors: | Hongjie Qian (Author), Jie Cheng (Author), Yuzhou Gui (Author), Wei Wang (Author), Liyu Liang (Author), Huijuan Zhu (Author), Qingqing Wu (Author), Meixian Ou (Author), Qian Chen (Author), Chen Yu (Author), Jingying Jia (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
by: Hong Zhang, et al.
Published: (2021) -
Tocilizumab (Actemra)
by: Martin Sheppard, et al.
Published: (2017) -
LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects
by: Guoying Cao, et al.
Published: (2023) -
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
by: Rania M. Sarhan, et al.
Published: (2022) -
Tocilizumab-Induced Erythema Annulare Centrifugum
by: Ana Luísa João, et al.
Published: (2022)